Online citations, reference lists, and bibliographies.
← Back to Search

Nanomedicine In Cancer Treatment

J. Kim, M. Cho
Published 2014 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
This paper references
10.1073/PNAS.92.16.7297
A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine.
O. Boussif (1995)
10.1016/j.jconrel.2010.08.027
To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery.
F. Danhier (2010)
10.1073/pnas.1003388107
Magnetic resonance monitoring of focused ultrasound/magnetic nanoparticle targeting delivery of therapeutic agents to the brain
H. Liu (2010)
10.1023/A:1026170830782
Starlike vs. Classic Macromolecular Prodrugs: Two Different Antibody-Targeted HPMA Copolymers of Doxorubicin Studied in Vitro and in Vivo as Potential Anticancer Drugs
M. Jelínková (2004)
10.2174/138161210791920496
Factors that control the circulation time of nanoparticles in blood: challenges, solutions and future prospects.
Jin-Wook Yoo (2010)
10.1002/ijc.23381
Synergistic antitumor activity of the novel SN‐38‐incorporating polymeric micelles, NK012, combined with 5‐fluorouracil in a mouse model of colorectal cancer, as compared with that of irinotecan plus 5‐fluorouracil
T. Nakajima (2008)
10.1002/smll.201000903
Synthesis of superparamagnetic CaCO3 mesocrystals for multistage delivery in cancer therapy.
Y. Zhao (2010)
10.1158/1078-0432.CCR-04-2291
Comparative Preclinical and Clinical Pharmacokinetics of a Cremophor-Free, Nanoparticle Albumin-Bound Paclitaxel (ABI-007) and Paclitaxel Formulated in Cremophor (Taxol)
A. Sparreboom (2005)
10.1038/42218
Biodegradable block copolymers as injectable drug-delivery systems
B. Jeong (1997)
10.1002/POLA.10301
Discovery of dendrimers and dendritic polymers: A brief historical perspective*
D. Tomalia (2002)
10.1002/MRM.1910310102
Dendrimer‐based metal chelates: A new class of magnetic resonance imaging contrast agents
E. C. Wiener (1994)
10.1016/J.BIOMATERIALS.2006.05.016
Trastuzumab-modified nanoparticles: optimisation of preparation and uptake in cancer cells.
I. Steinhauser (2006)
10.3109/02652049809006831
Polymer-coated long-circulating microparticulate pharmaceuticals.
V. Torchilin (1998)
10.1016/S0168-3659(97)00039-4
Block copolymer micelles for drug delivery: Loading and release of doxorubicin
G. Kwon (1997)
10.1016/0378-5173(93)90015-8
A new in vitro technique for the evaluation of drug release profile from colloidal carriers - ultrafiltration technique at low pressure
B. Magenheim (1993)
10.1016/J.NANO.2005.06.004
Role of nanotechnology in targeted drug delivery and imaging: a concise review.
O. Koo (2005)
10.1021/JA048548J
Cytotoxicity, hemolysis, and acute in vivo toxicity of dendrimers based on melamine, candidate vehicles for drug delivery.
Hui-Ting Chen (2004)
10.1016/0168-3659(94)90250-X
Synthesis of albumin-dextran sulfate microspheres possessing favourable loading and release characteristics for the anticancer drug doxorubicin
Y. Chen (1994)
10.1200/JCO.20.6.1668
Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin.
L. Seymour (2002)
10.3322/caac.21166
Cancer statistics, 2013
R. Siegel (2013)
10.1006/BBRC.1999.0177
Toward selection of internalizing antibodies from phage libraries.
B. Becerril (1999)
10.1016/S1476-5586(03)80046-5
Isolation of a colon tumor specific binding peptide using phage display selection.
K. Kelly (2003)
10.1016/j.drup.2011.01.003
Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
Alina Shapira (2011)
10.1016/j.coi.2013.03.007
The repertoire of human tumor-associated epitopes--identification and selection of antigens and their application in clinical trials.
S. Haen (2013)
10.2147/IJN.S15479
Integrin αvβ3-targeted gold nanoshells augment tumor vasculature-specific imaging and therapy
H. Xie (2011)
10.1002/smll.200901557
Near-infrared-resonant gold/gold sulfide nanoparticles as a photothermal cancer therapeutic agent.
A. Gobin (2010)
10.1016/j.ijpharm.2012.08.042
Polymeric micelles and alternative nanonized delivery vehicles for poorly soluble drugs.
Y. Lu (2013)
10.1073/PNAS.95.4.1735
Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer.
R. Reiter (1998)
10.1016/S0142-9612(00)00203-9
Poly(ethylenimine)-mediated gene delivery affects endothelial cell function and viability.
W. Godbey (2001)
10.1517/14712598.5.12.1557
Nanoscale polymer carriers to deliver chemotherapeutic agents to tumours
Mateja Cegnar (2005)
10.1016/j.biomaterials.2011.11.024
Suppression of tumor growth in H-ras12V liver cancer mice by delivery of programmed cell death protein 4 using galactosylated poly(ethylene glycol)-chitosan-graft-spermine.
Jihye Kim (2012)
10.2147/IJN.S4241
Nanoparticles and cancer therapy: A concise review with emphasis on dendrimers
D. Bharali (2009)
Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells.
J. Pinto (1996)
10.3978/j.issn.2224-4336.2013.04.05
Relapsed acute myeloblastic leukemia: first pediatric randomized study.
J. Styczyński (2013)
10.1259/bjr/42612922
Micro-CT enables microlocalisation and quantification of Her2-targeted gold nanoparticles within tumour regions.
J. Hainfeld (2011)
10.1023/A:1012128907225
Chitosan and Chitosan/Ethylene Oxide-Propylene Oxide Block Copolymer Nanoparticles as Novel Carriers for Proteins and Vaccines
P. Calvo (2004)
10.1016/j.urolonc.2007.03.015
Nanoparticles for drug delivery in cancer treatment.
B. Haley (2008)
10.1039/c0cs00097c
Design of biocompatible dendrimers for cancer diagnosis and therapy: current status and future perspectives.
Y. Cheng (2011)
10.1016/J.PROGPOLYMSCI.2007.09.003
Polymeric nanomedicine for cancer therapy
J. Park (2008)
10.1002/1097-0142(19940501)73:9<2432::AID-CNCR2820730929>3.0.CO;2-S
Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications
J. Ross (1994)
10.1007/s12094-012-0766-6
Nanoparticle delivery systems for cancer therapy: advances in clinical and preclinical research
S. P. Egusquiaguirre (2012)
Long-circulating and target-specific nanoparticles: theory to practice.
S. Moghimi (2001)
10.1016/j.jconrel.2011.05.025
Targeted chemoimmunotherapy using drug-loaded aptamer-dendrimer bioconjugates.
I. Lee (2011)
10.1007/s00005-009-0051-8
Cardiomyocyte death in doxorubicin-induced cardiotoxicity
Y. Zhang (2009)
10.1158/1078-0432.CCR-09-0522
A Phase I Study of a 2-Day Lapatinib Chemosensitization Pulse Preceding Nanoparticle Albumin-Bound Paclitaxel for Advanced Solid Malignancies
A. Chien (2009)
10.1016/S0939-6411(99)00039-9
Polymeric micelles - a new generation of colloidal drug carriers.
M. Jones (1999)
10.1158/0008-5472.CAN-08-3231
In vivo off-resonance saturation magnetic resonance imaging of alphavbeta3-targeted superparamagnetic nanoparticles.
C. Khemtong (2009)
10.1016/j.ejca.2009.05.016
Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer.
I. Vergote (2009)
10.1038/sj.bjc.6602204
Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin
Y. Matsumura (2004)
10.1080/02841850902902557
Specific targeting of breast tumor by octreotide-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 3.0-tesla magnetic resonance scanner
Xubin Li (2009)
10.2147/IJN.S29152
Suppression of lung cancer progression by biocompatible glycerol triacrylate–spermine-mediated delivery of shAkt1
S. Hong (2012)
10.1016/j.drup.2010.04.002
Progress in the unraveling of the endoplasmic reticulum stress/autophagy pathway and cancer: implications for future therapeutic approaches.
S. Schleicher (2010)
10.1088/0022-3727/36/13/201
TOPICAL REVIEW: Applications of magnetic nanoparticles in biomedicine
Q. Pankhurst (2003)
10.1002/ijc.21731
The global health burden of infection‐associated cancers in the year 2002
D. Parkin (2006)
10.1200/JCO.2005.04.937
Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer.
W. Gradishar (2005)
10.1021/NL048037V
Stereocomplex block copolymer micelles: core-shell nanostructures with enhanced stability.
Ning Kang (2005)
10.1080/14733400410001727592
Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells.
C. Mamot (2003)
10.1158/1078-0432.CCR-06-0946
Vascular Targeted Nanoparticles for Imaging and Treatment of Brain Tumors
G. R. Reddy (2006)
10.1021/MP060039W
Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells.
Shyh-Dar Li (2006)
10.1016/J.JCONREL.2006.10.025
Chitosan-graft-polyethylenimine as a gene carrier.
Hu-Lin Jiang (2007)
10.1211/0022357021771887
Vehicles for oligonucleotide delivery to tumours
C. Dass (2002)
10.1158/0008-5472.CAN-04-2550
Nanoparticle-Aptamer Bioconjugates
O. Farokhzad (2004)
10.4028/www.scientific.net/KEM.342-343.457
Glucosylated Polypropylenimine Dendrimer as a Novel Gene Carrier
Y. K. Kim (2007)
10.1016/j.pharmthera.2010.07.007
Emerging nanomedicines for early cancer detection and improved treatment: current perspective and future promise.
D. Bharali (2010)
10.1080/10717540490433895
Colloidal Gold: A Novel Nanoparticle Vector for Tumor Directed Drug Delivery
G. Paciotti (2004)
10.1021/BC025529V
Polyethylenimine-graft-poly(ethylene glycol) copolymers: influence of copolymer block structure on DNA complexation and biological activities as gene delivery system.
H. Petersen (2002)
10.1023/A:1015000503629
Inhibition of P-Glycoprotein by D-α-Tocopheryl Polyethylene Glycol 1000 Succinate (TPGS)
J. M. Dintaman (2004)
10.1016/J.BIOMATERIALS.2007.05.006
Development of gelatin nanoparticles with biotinylated EGF conjugation for lung cancer targeting.
Ching-Li Tseng (2007)
10.1038/sj.clpt.6100400
Nanoparticles in Medicine: Therapeutic Applications and Developments
L. Zhang (2008)
10.1016/j.nano.2009.01.009
A randomized multicenter phase II clinical trial of mitoxantrone-loaded nanoparticles in the treatment of 108 patients with unresected hepatocellular carcinoma.
Qinghua Zhou (2009)
10.1021/bm100141y
Construction of a star-shaped copolymer as a vector for FGF receptor-mediated gene delivery in vitro and in vivo.
D. Li (2010)
10.2174/092986712800784667
Antibody-conjugated nanoparticles for therapeutic applications.
M. M. Cardoso (2012)
10.1038/nrclinonc.2009.128
Neurological adverse effects caused by cytotoxic and targeted therapies
D. Schiff (2009)
10.1007/s10552-007-9083-8
Quantifying the role of PSA screening in the US prostate cancer mortality decline
Ruth Etzioni (2007)
10.1517/17425240903436479
Polymeric micelles as a new drug carrier system and their required considerations for clinical trials
M. Yokoyama (2010)
10.1038/386671A0
Mechanisms of angiogenesis
W. Risau (1997)
10.1016/j.addr.2008.08.005
Active targeting schemes for nanoparticle systems in cancer therapeutics.
J. D. Byrne (2008)
10.1002/smll.201000134
A new era for cancer treatment: gold-nanoparticle-mediated thermal therapies.
Laura C. Kennedy (2011)
10.1016/j.biomaterials.2010.11.068
N-acetylgalactosamine-functionalized dendrimers as hepatic cancer cell-targeted carriers.
S. Medina (2011)
10.3109/1061186031000150791
Magnetic Drug Targeting—Biodistribution of the Magnetic Carrier and the Chemotherapeutic agent Mitoxantrone after Locoregional Cancer Treatment
C. Alexiou (2003)
10.1007/s12274-012-0200-y
A functionalized graphene oxide-iron oxide nanocomposite for magnetically targeted drug delivery, photothermal therapy, and magnetic resonance imaging
X. Ma (2012)
10.1016/j.jconrel.2008.03.010
Preparation and characterization of PE38KDEL-loaded anti-HER2 nanoparticles for targeted cancer therapy.
H. Chen (2008)
10.1038/nature08956
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
M. Davis (2010)
10.1016/J.JCONREL.2004.03.007
Enhanced in vitro DNA transfection efficiency by novel folate-linked nanoparticles in human prostate cancer and oral cancer.
Y. Hattori (2004)
10.1002/MACP.1987.021880604
Solution properties of drug carriers based on poly[N-(2-hydroxypropyl)methacrylamide] containing biodegradable bonds
K. Ulbrich (1987)
10.1016/S0169-409X(01)00230-7
Cyclodextrins in oligonucleotide delivery.
E. Redenti (2001)
10.1038/nrc2394
Paul Ehrlich's magic bullet concept: 100 years of progress
K. Strebhardt (2008)
10.1002/BIT.20356
Cyclodextrin-polyethylenimine conjugates for targeted in vitro gene delivery.
M. L. Forrest (2005)
10.1038/sj.bjc.6602772
Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats
H. Uchino (2005)
10.1038/sj.bjc.6601856
Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer
S. Danson (2004)
10.2165/00003495-200767090-00006
HER2-Positive Breast Cancer
Ryan H Engel (2012)
10.1016/J.BIOMATERIALS.2006.11.018
Quantum-dot based nanoparticles for targeted silencing of HER2/neu gene via RNA interference.
W. B. Tan (2007)
10.1073/PNAS.0601755103
Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo.
O. Farokhzad (2006)
10.1039/c0cs00019a
Cyclodextrin-based gene delivery systems.
C. Ortiz Mellet (2011)
10.1002/JPS.2600840721
Pefloxacine mesilate- and ofloxacin-loaded polyethylcyanoacrylate nanoparticles: characterization of the colloidal drug carrier formulation.
M. Fresta (1995)
10.1016/j.canlet.2008.04.024
Tumor targeting of vincristine by mBAFF-modified PEG liposomes in B lymphoma cells.
L. Zhang (2008)
10.1146/annurev-med-040210-162544
Nanoparticle delivery of cancer drugs.
A. Wang (2012)
10.1016/j.yexmp.2008.12.004
Nanoparticle-based targeted drug delivery.
R. Singh (2009)
10.1016/0168-3659(92)90199-2
A new class of drug carriers: micelles of poly(oxyethylene)-poly(oxypropylene) block copolymers as microcontainers for drug targeting from blood in brain☆
A. V. Kabanov (1992)
10.1021/CR970025P
Cyclodextrin Drug Carrier Systems.
K. Uekama (1998)
10.1345/aph.18425
Fluorouracil-Induced Neurotoxicity
N. Pirzada (2000)
Treatment of solid L1210 murine tumors with local hyperthermia and temperature-sensitive liposomes containing methotrexate.
J. Weinstein (1980)
10.1016/S0169-409X(98)00003-9
Control of tumour vascular permeability.
Baban (1998)
10.1016/J.TIBTECH.2007.02.005
Applications of nanoparticles to diagnostics and therapeutics in colorectal cancer.
P. Fortina (2007)
10.1016/S0168-3659(01)00537-5
The effect of fatty acid substitution on the in vitro release of amphotericin B from micelles composed of poly(ethylene oxide)-block-poly(N-hexyl stearate-L-aspartamide).
A. Lavasanifar (2002)
10.1021/BM000142L
Glutathione-sensitive stabilization of block copolymer micelles composed of antisense DNA and thiolated poly(ethylene glycol)-block-poly(L-lysine): a potential carrier for systemic delivery of antisense DNA.
Y. Kakizawa (2001)
10.1002/DDR.20066
Colloidal gold nanoparticles: a novel nanoparticle platform for developing multifunctional tumor‐targeted drug delivery vectors
G. Paciotti (2006)
10.1002/cncr.24760
Annual report to the nation on the status of cancer, 1975‐2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates
B. Edwards (2010)
10.1038/sj.leu.2401921
A phase I/II study of multiple-dose intravenous busulfan as myeloablation prior to stem cell transplantation
E. Olavarría (2000)
10.1200/JCO.1996.14.8.2353
Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma.
P. Gill (1996)
10.1158/1078-0432.CCR-03-0035
Novel Temperature-Sensitive Liposomes with Prolonged Circulation Time
L. Lindner (2004)
10.1021/BC050348P
HER2 specific tumor targeting with dendrimer conjugated anti-HER2 mAb.
R. Shukla (2006)
10.1021/BC025541N
Biodegradable, endosome disruptive, and cationic network-type polymer as a highly efficient and nontoxic gene delivery carrier.
Y. Lim (2002)
10.1042/BST0350061
Dendrimers as multi-purpose nanodevices for oncology drug delivery and diagnostic imaging.
D. Tomalia (2007)
10.1200/JCO.2008.18.9548
Phase II evaluation of nanoparticle albumin-bound paclitaxel in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer.
M. Teneriello (2009)
10.1158/1535-7163.MCT-05-0433
Aerosol delivery of urocanic acid–modified chitosan/programmed cell death 4 complex regulated apoptosis, cell cycle, and angiogenesis in lungs of K-ras null mice
H. Jin (2006)
10.1016/J.DRUDIS.2006.07.005
Exploiting the enhanced permeability and retention effect for tumor targeting.
A. Iyer (2006)
10.1021/JA016812S
Synthesis of highly crystalline and monodisperse maghemite nanocrystallites without a size-selection process.
T. Hyeon (2001)
Colon Cancer Vaccines : An Update
E. Merika (2010)
10.1073/pnas.0914140107
Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles
C. Choi (2009)
10.1016/S0169-409X(02)00047-9
Pluronic block copolymers for overcoming drug resistance in cancer.
A. Kabanov (2002)
10.1016/J.BIOMATERIALS.2006.09.047
Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery.
J. Cheng (2007)
10.1016/j.jconrel.2012.03.020
Doxil®--the first FDA-approved nano-drug: lessons learned.
Y. Barenholz (2012)
10.1002/1097-0142(19950415)75:8<2169::AID-CNCR2820750822>3.0.CO;2-H
Hand‐foot syndrome associated with liposome‐encapsulated doxorubicin therapy
K. Gordon (1995)
10.1016/J.BBRC.2005.05.132
Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy.
N. Ferrara (2005)
10.1007/978-1-4757-3147-7_4
The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer.
M. Pegram (2000)
10.1002/SMLL.200400093
Gold nanoparticles are taken up by human cells but do not cause acute cytotoxicity.
E. E. Connor (2005)
10.1158/0008-5472.CAN-05-1093
Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo.
C. Mamot (2005)
10.1016/J.JCONREL.2006.09.012
PEGylated lysine dendrimers for tumor-selective targeting after intravenous injection in tumor-bearing mice.
Tatsuya Okuda (2006)
10.1021/JS950204R
Preparation and Characterization of the Micelle-Forming Polymeric Drug Indomethacin-lncorporated Polyfethylene oxide)-Poly(β-benzyl L-aspartate) Block Copolymer Micelles
Sung Bum La (1996)
10.1038/sj.bjc.6603855
A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation
T. Hamaguchi (2007)
10.1016/J.JCONREL.2003.09.016
Cellular association and cytotoxicity of anti-CD74-targeted lipid drug-carriers in B lymphoma cells.
B. Lundberg (2004)
10.3892/OR.12.5.1059
A multi-center, late phase II clinical trial of Genexol (paclitaxel) and cisplatin for patients with advanced gastric cancer.
S. Park (2004)
10.1016/J.CHEMBIOL.2004.10.016
Synthesis and functional evaluation of DNA-assembled polyamidoamine dendrimer clusters for cancer cell-specific targeting.
Youngseon Choi (2005)
10.1158/1535-7163.MCT-05-0161
Vascular endothelial growth factor selectively targets boronated dendrimers to tumor vasculature
M. Backer (2005)
10.1007/s10549-007-9591-y
Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer
K. Lee (2007)
10.1158/0008-5472.CAN-06-1605
Novel SN-38-incorporating polymeric micelles, NK012, eradicate vascular endothelial growth factor-secreting bulky tumors.
F. Koizumi (2006)
10.1038/nrc1958
Polymer conjugates as anticancer nanomedicines
R. Duncan (2006)
10.1016/J.PLIPRES.2004.12.001
Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release.
T. Andresen (2005)
10.1038/71889
Synthetic DNA delivery systems
D. Luo (2000)
10.1073/PNAS.95.8.4607
Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment.
S. Hobbs (1998)
Monoclonal antibody covalently coupled with fatty acid. A reagent for in vitro liposome targeting.
A. Huang (1980)
10.1002/1097-4636(200110)57:1<92::AID-JBM1146>3.0.CO;2-1
Effect of molecular weight of thermoreversible polymer on in vivo retention of rhBMP-2.
T. Gao (2001)
10.3816/CBC.2010.n.036
Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer.
A. Conlin (2010)
10.1080/10611860802088598
Long circulating PEGylated poly(d,l-lactide-co-glycolide) nanoparticulate delivery of Docetaxel to solid tumors
M. Senthilkumar (2008)
10.1002/ijc.20452
Anisamide‐targeted stealth liposomes: A potent carrier for targeting doxorubicin to human prostate cancer cells
R. Banerjee (2004)
10.1016/J.PHARMTHERA.2006.05.006
Current state, achievements, and future prospects of polymeric micelles as nanocarriers for drug and gene delivery.
N. Nishiyama (2006)
10.1002/AIC.690491202
Advances in Biomaterials, Drug Delivery, and Bionanotechnology
R. Langer (2003)
10.3109/1061186X.2012.712130
Nanoparticles-mediated drug delivery approaches for cancer targeting: a review
S. Sultana (2013)
10.1007/BF00409698
Vascularization of tumors: A review
P. Shubik (2004)
10.1021/AR7000815
Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases.
P. Low (2008)
Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
J. Park (2002)
10.1002/anie.201206416
Enzyme-responsive controlled release of covalently bound prodrug from functional mesoporous silica nanospheres.
A. Popat (2012)
10.1038/sj.cgt.7700844
Folate-linked nanoparticle-mediated suicide gene therapy in human prostate cancer and nasopharyngeal cancer with herpes simplex virus thymidine kinase
Y. Hattori (2005)
10.1093/annonc/mdn661
Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531).
V. Roy (2009)
10.1002/cmdc.200800030
Molecular Recognition of Small‐Cell Lung Cancer Cells Using Aptamers
H. W. Chen (2008)
10.1038/sj.gt.3302997
Galactosylated chitosan-graft-polyethylenimine as a gene carrier for hepatocyte targeting
H-L Jiang (2007)
10.2217/14796694.2.6.705
Opportunities for near-infrared thermal ablation of colorectal metastases by guanylyl cyclase C-targeted gold nanoshells.
S. Waldman (2006)
10.1016/S0378-5173(03)00128-5
Development of polymeric nanoparticulate drug delivery systems: evaluation of nanoparticles based on biotinylated poly(ethylene glycol) with sugar moiety.
I. Kim (2003)
10.1002/jgm.696
Exploring polyethylenimine‐mediated DNA transfection and the proton sponge hypothesis
A. Akinc (2005)
10.1196/annals.1348.001
Surface‐Modified LPD Nanoparticles for Tumor Targeting
Shyh-Dar Li (2006)
10.1016/j.jconrel.2010.06.004
Gold nanoparticle platforms as drug and biomacromolecule delivery systems.
Bradley M. Duncan (2010)
10.1016/j.ijpharm.2010.04.027
Dendrimer toxicity: Let's meet the challenge.
K. Jain (2010)
10.1016/S0168-3659(98)00120-5
In vitro release of 5-fluorouracil with cyclic core dendritic polymer.
R. Zhuo (1999)
10.1038/sj.cgt.7701116
Urocanic acid-modified chitosan-mediated PTEN delivery via aerosol suppressed lung tumorigenesis in K-rasLA1 mice
H. Jin (2008)
10.1016/j.jconrel.2010.04.004
Tumor-homing multifunctional nanoparticles for cancer theragnosis: Simultaneous diagnosis, drug delivery, and therapeutic monitoring.
K. Kim (2010)
10.1016/S0140-6736(05)67625-8
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
N. Thatcher (2005)
10.1016/S1359-6446(01)01757-3
Poly(amidoamine) (PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications.
R. Esfand (2001)
10.1023/A:1007552007765
Biodegradable Polyester, Poly[α-(4-Aminobutyl)-l-Glycolic Acid], as a Non-Toxic Gene Carrier
Y. Lim (2004)
10.1016/J.REACTFUNCTPOLYM.2010.10.009
Polymeric micelles for nano-scale drug delivery
K. Miyata (2011)
10.1158/0008-5472.CAN-04-3921
Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer.
J. Kukowska-Latallo (2005)
10.1208/pt060243
Cyclodextrins in drug delivery: An updated review
R. Challa (2008)
10.1016/S0168-3659(01)00341-8
Development of the polymer micelle carrier system for doxorubicin.
T. Nakanishi (2001)
10.1111/j.1349-7006.2009.01103.x
Preclinical and clinical studies of anticancer agent‐incorporating polymer micelles
Y. Matsumura (2009)
10.1016/0277-5379(91)90275-I
In vitro evaluation of the association of thermosensitive liposome-encapsulated doxorubicin with hyperthermia.
J. Merlin (1991)
10.1016/J.IJPHARM.2005.10.010
Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles.
Donald E. Owens (2006)
10.1016/j.biomaterials.2012.07.012
Anisamide-targeted cyclodextrin nanoparticles for siRNA delivery to prostate tumours in mice.
Jianfeng Guo (2012)
10.1016/j.jconrel.2009.08.006
Development of a highly stable and targetable nanoliposomal formulation of topotecan.
D. Drummond (2010)
10.1016/S0939-6411(03)00155-3
Chitosan-DNA nanoparticles as non-viral vectors in gene therapy: strategies to improve transfection efficacy.
Sania Mansouri (2004)
10.1016/J.CANLET.2005.07.001
Altered iron metabolism, transferrin receptor 1 and ferritin in patients with colon cancer.
M. Prutki (2006)
10.1166/JNN.2010.2239
Folate conjugated poly(ester amine) for lung cancer therapy.
R. Arote (2010)
10.1200/JCO.2001.19.5.1444
Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.
G. Batist (2001)
10.1016/S0168-3659(03)00076-2
Low-molecular-weight polyethylenimine as a non-viral vector for DNA delivery: comparison of physicochemical properties, transfection efficiency and in vivo distribution with high-molecular-weight polyethylenimine.
K. Kunath (2003)
10.3816/CBC.2010.n.011
A phase II neoadjuvant trial of sequential nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide in locally advanced breast cancer.
A. Robidoux (2010)
10.1016/j.nano.2011.04.004
Design and potential application of PEGylated gold nanoparticles with size-dependent permeation through brain microvasculature.
A. Etame (2011)
10.1016/S0168-3659(98)00054-6
Incorporation of water-insoluble anticancer drug into polymeric micelles and control of their particle size.
M. Yokoyama (1998)
10.1016/j.biomaterials.2010.07.005
Core-crosslinked polymeric micelles with controlled release of covalently entrapped doxorubicin.
M. Talelli (2010)
10.1021/nn103047r
Tumor regression in vivo by photothermal therapy based on gold-nanorod-loaded, functional nanocarriers.
W. I. Choi (2011)
10.1056/NEJMOA050518
Effect of screening and adjuvant therapy on mortality from breast cancer.
D. Berry (2005)
10.1016/J.ADDR.2004.02.014
Nanoparticle and targeted systems for cancer therapy.
L. Brannon-Peppas (2004)
10.1016/0277-5379(83)90408-X
Selective targeting of magnetic albumin microspheres containing low-dose doxorubicin: total remission in Yoshida sarcoma-bearing rats.
K. Widder (1983)
10.1016/S0959-8049(01)00171-X
Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation.
H. Gelderblom (2001)
10.1016/j.biomaterials.2010.04.043
Polyethyleneimine-modified iron oxide nanoparticles for brain tumor drug delivery using magnetic targeting and intra-carotid administration.
B. Chertok (2010)
10.1002/cncr.10201
Liposome‐encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first‐line therapy of metastatic breast carcinoma
L. Harris (2002)
10.1002/ANIE.200504599
Laser-induced release of encapsulated materials inside living cells.
A. Skirtach (2006)
10.1038/mt.2012.185
The possible "proton sponge " effect of polyethylenimine (PEI) does not include change in lysosomal pH.
R. V. Benjaminsen (2013)
10.1016/S0167-4889(02)00256-2
Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis.
U. Nielsen (2002)
10.1039/B300320P
Size-controlled synthesis of thiol-derivatized gold clusters
G. Carotenuto (2003)
10.1080/10428190500052438
The use of liposomal daunorubicin (DaunoXome) in acute myeloid leukemia
A. Fassas (2005)
10.1007/s10549-006-9199-7
LHRH-conjugated Magnetic Iron Oxide Nanoparticles for Detection of Breast Cancer Metastases
C. Leuschner (2006)
10.1016/j.biomaterials.2008.11.027
Galactosylated fluorescent labeled micelles as a liver targeting drug carrier.
De-Qun Wu (2009)
10.1016/j.tips.2009.08.004
Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer.
Y. Malam (2009)
10.1021/mp800049w
Pharmacokinetics and biodistribution of nanoparticles.
Shyh-Dar Li (2008)
10.1021/bc9002212
Tamoxifen-poly(ethylene glycol)-thiol gold nanoparticle conjugates: enhanced potency and selective delivery for breast cancer treatment.
Erik C Dreaden (2009)
10.1517/17425247.2.1.335
Cyclodextrins in drug delivery
T. Loftsson (2005)
10.1093/ANNONC/MDH097
Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.
M. O'Brien (2004)
10.1016/J.ADDR.2005.09.019
Dendrimer biocompatibility and toxicity.
R. Duncan (2005)
10.1006/CYTO.1997.0208
Mitigating effects of interleukin 11 on consecutive courses of 5-fluorouracil-induced ulcerative mucositis in hamsters.
S. Sonis (1997)
10.1016/j.jconrel.2011.12.012
Polymeric micelles drug delivery system in oncology.
Jian Gong (2012)
10.1007/s00018-009-0053-z
Nanocarriers’ entry into the cell: relevance to drug delivery
H. Hillaireau (2009)
10.1016/J.IJPHARM.2007.04.037
Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes.
H. Hatakeyama (2007)
10.1038/sj.bjc.6602479
NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel
T. Hamaguchi (2005)
10.1016/j.biomaterials.2009.11.047
Peptide-conjugated biodegradable nanoparticles as a carrier to target paclitaxel to tumor neovasculature.
D. Yu (2010)
10.1158/0008-5472.CAN-05-4199
Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models.
D. Kirpotin (2006)
10.1021/BC0603889
Surface acetylation of polyamidoamine (PAMAM) dendrimers decreases cytotoxicity while maintaining membrane permeability.
Rohit B. Kolhatkar (2007)
10.1016/j.nano.2010.05.005
Advances in polymeric micelles for drug delivery and tumor targeting.
U. Kedar (2010)
10.1023/A:1016266523505
Physical Entrapment of Adriamycin in AB Block Copolymer Micelles
G. Kwon (2004)
10.1016/J.EJPB.2004.11.011
Polyethylenimine-based non-viral gene delivery systems.
U. Lungwitz (2005)



Semantic Scholar Logo Some data provided by SemanticScholar